| Literature DB >> 24884544 |
Jan-Willem Weenink1, Jozé Braspenning, Michel Wensing.
Abstract
BACKGROUND: Patient reported outcome measures (PROMs) have been introduced in studies to assess healthcare performance. The development of PROMs for primary care poses specific challenges, including a preference for generic measures that can be used across diseases, including early phases or mild conditions. This pilot study aimed to explore the potential usefulness of seven generic measures for assessing health outcomes in primary care patients.Entities:
Mesh:
Year: 2014 PMID: 24884544 PMCID: PMC4029823 DOI: 10.1186/1471-2296-15-88
Source DB: PubMed Journal: BMC Fam Pract ISSN: 1471-2296 Impact factor: 2.497
Possible outcome domains for PROMS following from the WONCA definition of general practice
| Comprehensive approach | Promotes health and well-being | General-, physical and mental health |
| Person-centred care | Promotes patient empowerment | Patient empowerment |
| Centred on patient and context | Patient enablement |
Domains and used questionnaires
| Patient Empowerment | Patient Activation Measure (PAM-13) |
| | Effective Consumer Scale (EC-17) |
| General Health | EuroQol 5D (EQ-5D, including EQ-VAS) |
| | Short Form 12 (SF-12) |
| Mental Health | General Health Questionnaire (GHQ-12) |
| Enablement | Patient Enablement Instrument (PEI) |
| Effect | Global Perceived Effect (GPE) |
Patients’ characteristics (n = 98)
| Mean age (SD) | 62.5 (12.2) |
| Percentage women | 44.2% |
| Percentage with higher education | 34.7% |
| Percentage with single household | 18.3% |
| Percentage of Dutch decent | 99.0% |
| Percentage with one or more chronic illnesses | 55.1%a |
aIncluded asthma, cardiovascular disease, COPD, depression and diabetes.
Response on individual measures
| PAM-13 | 13 | 95.9% (47/49) | 43 | 4 | - | - | 45 | 2 | - | - |
| EC-17a | 17 | 91.8% (45/49) | 43 | 1 | 1 | - | 39 | 5 | 1 | - |
| EQ-5D | 5 | 94.0% (45/50) | 42 | 3 | - | - | 43 | 2 | - | - |
| EQ- VASb | 1 | 94.0% (47/50) | 47 | | | | 47 | | | |
| SF-12 | 12 | 87.5% (42/48) | 42 | - | - | - | 42 | - | - | - |
| GHQ-12 | 12 | 99.0% (97/98) | 94 | 2 | 1 | - | 94 | 3 | - | - |
| PEI | 6 | 99.0% (97/98) | 94 | 1 | - | 2 | 92 | - | 2 | 3 |
| GPEb | 1 | 90.8% (89/98) | 89 | 89 | ||||||
aIf 3 or more items were missing or not applicable no total score was computed; 36 total scores computed (73.5%).
bInstrument consists of 1 item.
Total scores and change of scores on individual measures (n = 98)
| | | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAM-13 (47) | 0 - 100 | 56.4 | 41.7 | 100.0 | 49.9 - 70.8 | 56.4 | 40.1 | 100.0 | 49.9 - 70.8 | 0.0 | −43.6 | 38.9 | −2.8 to 6.7 |
| EC-17 (36)a | 0 - 100 | 76.5 | 55.9 | 100.0 | 75.0 - 83.8 | 80.3 | 63.2 | 98.5 | 75.0 - 88.1 | 0.0 | −10.9 | 36.8 | −2.4 to 4.4 |
| EQ-5D (45) | 0 - 1 | 0.84 | 0.15 | 1.00 | 0.79 - 0.89 | 0.84 | 0.25 | 1.00 | 0.81 - 1.0 | 0.00c | −0.44 | 0.28 | 0.00 to 0.11 |
| EQ- VAS (47) | 0 - 100 | 70.0 | 30 | 100 | 60.0 - 80.0 | 75.0 | 40 | 100 | 70.0 - 80.0 | 0.0 | −25.0 | 20.0 | −5.0 to 10.0 |
| SF-12 PCS (42) | 0 - 100 | 42.3 | 18.7 | 60.5 | 32.4 - 53.5 | 49.8 | 17.8 | 58.9 | 37.5 - 54.4 | 2.0c | −15.3 | 28.8 | −1.3 to 7.1 |
| SF-12 MCS (42) | 0 - 100 | 56.0 | 17.3 | 65.8 | 48.7 - 59.0 | 54.1 | 19.8 | 62.7 | 49.3 - 58.9 | 0.0 | −25.8 | 20.9 | −6.3 to 4.4 |
| GHQ-12 (97) | 0 - 36b | 9.0 | 3.0 | 26.0 | 7.0 - 13.0 | 8.0 | 3.0 | 25.0 | 7.0 - 12.0 | 0.0 | −13.0 | 10.0 | −2.0 to 2.0 |
| PEI (97) | 0 - 12 | 0.0 | 0.0 | 6.0 | 0.0 - 2.5 | 0.0 | 0.0 | 12.0 | 0.0 - 2.0 | 0.0 | −6.0 | 8.0 | −0.5 to 0.0 |
| GPE (89) | 1 - 7 | 4.0 | 2 | 7 | 4.0 - 5.0 | 4.0 | 3 | 7 | 4.0 - 6.0 | 0.0 c | −3.0 | 3.0 | 0.0 to 1.0 |
aIf 3 or more items missing then no score was computed.
bLower score means better health.
cMean score difference significant with p ≤ 0.05.
Floor and ceiling effects
| PAM-13 (47) | 0.0% (0/47) | 2.1% (1/47) | 0.0% (0/47) | 2.1% (1/47) |
| EC-17 (36) | 0.0% (0/36) | 2.8% (1/36) | 0.0% (0/36) | 0.0% (0/36) |
| EQ-5D (45) | 0.0% (0/45) | 22.2% (10/45) | 0.0% (0/45) | 44.4% (20/45) |
| EQ- VAS (47) | 0.0% (0/47) | 2.1% (1/47) | 0.0% (0/47) | 6.4% (3/47) |
| SF-12 PCS (42) | 0.0% (0/42) | 0.0% (0/42) | 0.0% (0/42) | 0.0% (0/42) |
| SF-12 MCS (42) | 0.0% (0/42) | 0.0% (0/42) | 0.0% (0/42) | 0.0% (0/42) |
| GHQ-12 (97) | 0.0% (0/97) | 0.0% (0/97) | 0.0% (0/97) | 0.0% (0/97) |
| PEI (97) | 54.6% (53/97) | 0.0% (0/97) | 60.8% (59/97) | 1.0% (1/97) |
| GPE (89) | 1.1% (1/89) | 5.6% (5/89) | 0.0% (0/89) | 6.7% (6/89) |
Improved scores on individual measures (% of patients)
| PAM-13 (47) | 46.8% | 14.9% | 38.3% |
| EC-17 (36) | 47.2% | 19.4% | 33.3% |
| EQ-5D (45) | 40.0% | 46.7% | 13.3% |
| EQ- VAS (47) | 48.9% | 21.3% | 29.8% |
| SF-12 PCS (42) | 57.1% | 7.1% | 35.7% |
| SF-12 MCS (42) | 47.6% | 7.1% | 45.2% |
| GHQ-12 (97)a | 47.4% | 11.3% | 41.2% |
| PEI (97) | 22.7% | 52.6% | 24.7% |
| GPE (89) | 41.6% | 37.1% | 21.3% |
aLower total score on the GHQ reflects improved score.